Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 54

1.

Women's interest in taking tamoxifen and raloxifene for breast cancer prevention: response to a tailored decision aid.

Fagerlin A, Dillard AJ, Smith DM, Zikmund-Fisher BJ, Pitsch R, McClure JB, Greene S, Alford SH, Nair V, Hayes DF, Wiese C, Ubel PA.

Breast Cancer Res Treat. 2011 Jun;127(3):681-8. doi: 10.1007/s10549-011-1450-1.

2.

American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene.

Chlebowski RT, Collyar DE, Somerfield MR, Pfister DG.

J Clin Oncol. 1999 Jun;17(6):1939-55. Review.

PMID:
10561236
3.

The role of selective estrogen receptor modulators in the prevention of breast cancer: comparison of the clinical trials.

Martino S, Costantino J, McNabb M, Mershon J, Bryant K, Powles T, Secrest RJ.

Oncologist. 2004;9(2):116-25. Review.

4.

Chemoprevention of breast cancer. A joint guideline from the Canadian Task Force on Preventive Health Care and the Canadian Breast Cancer Initiative's Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer.

Levine M, Moutquin JM, Walton R, Feightner J; Canadian Task Force on Preventive Health Care and the Canadian Breast Cancer Initiative's Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer..

CMAJ. 2001 Jun 12;164(12):1681-90. Review.

5.

The NSABP Study of Tamoxifen and Raloxifene (STAR) trial.

Vogel VG.

Expert Rev Anticancer Ther. 2009 Jan;9(1):51-60. doi: 10.1586/14737140.9.1.51. Review. Erratum in: Expert Rev Anticancer Ther. 2009 Mar;9(3):388.

6.

Chemoprevention of breast cancer.

Dalton RR, Kallab AM.

South Med J. 2001 Jan;94(1):7-15. Review.

PMID:
11213947
7.

From adjuvant therapy to breast cancer prevention: BCPT and STAR.

Dunn BK, Ford LG.

Breast J. 2001 May-Jun;7(3):144-57. Review.

PMID:
11469927
8.

Breast cancer chemoprevention: current status and future directions.

Wickerham DL, Tan-Chiu E.

Semin Oncol. 2001 Jun;28(3):253-9. Review.

PMID:
11402435
9.

Chemoprevention of breast cancer: a summary of the evidence for the U.S. Preventive Services Task Force.

Kinsinger LS, Harris R, Woolf SH, Sox HC, Lohr KN.

Ann Intern Med. 2002 Jul 2;137(1):59-69. Review.

PMID:
12093250
10.

American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition.

Chlebowski RT, Col N, Winer EP, Collyar DE, Cummings SR, Vogel VG 3rd, Burstein HJ, Eisen A, Lipkus I, Pfister DG; American Society of Clinical Oncology Breast Cancer Technology Assessment Working Group..

J Clin Oncol. 2002 Aug 1;20(15):3328-43. Review.

PMID:
12149307
11.

Preventing breast cancer in high-risk women, 2008.

Vogel VG.

Oncology (Williston Park). 2008 May;22(6):666-73; discussion 679, 682, 684. Review.

12.

Chemoprevention of breast cancer: implications for postmenopausal women.

Fabian CJ, Kimler BF.

Drugs Aging. 2002;19(1):43-78. Review.

PMID:
11929326
13.

Chemoprevention or mastectomy for women at high risk of developing breast cancer.

Sismondi P, D'Alonzo M, Pecchio S, Bounous VE, Robba E, Biglia N.

Maturitas. 2015 Nov;82(3):271-3. doi: 10.1016/j.maturitas.2015.07.002. Review.

PMID:
26276104
14.

Risks, benefits, and effects on quality of life of selective estrogen-receptor modulator therapy in postmenopausal women at increased risk of breast cancer.

Ganz PA, Land SR.

Menopause. 2008 Jul-Aug;15(4 Suppl):797-803. doi: 10.1097/gme.0b013e31817be9af. Review.

PMID:
18596601
15.

Endocrine prevention of breast cancer using selective oestrogen receptor modulators (SORMs).

Lo SS, Vogel VG.

Best Pract Res Clin Endocrinol Metab. 2004 Mar;18(1):97-111. Review.

PMID:
14687600
16.

The role of selective estrogen receptor modulators on breast cancer: from tamoxifen to raloxifene.

Lee WL, Cheng MH, Chao HT, Wang PH.

Taiwan J Obstet Gynecol. 2008 Mar;47(1):24-31. doi: 10.1016/S1028-4559(08)60051-0. Review.

17.

Primary prevention of breast cancer: new approaches.

Cummings SR.

Maturitas. 2007 May 20;57(1):39-41. Review.

PMID:
17391879
18.

Chemoprevention of breast cancer in postmenopausal women.

Geller BA, Vogel VG.

Breast Dis. 2005-2006;24:79-92. Review.

PMID:
16917141
19.

SERMs for the treatment and prevention of breast cancer.

Swaby RF, Sharma CG, Jordan VC.

Rev Endocr Metab Disord. 2007 Sep;8(3):229-39. Review.

PMID:
17440819
20.

Supplemental Content

Support Center